These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38608689)

  • 1. Mutational rescue of the activity of high-fidelity Cas9 enzymes.
    Vos PD; Gandadireja AP; Rossetti G; Siira SJ; Mantegna JL; Filipovska A; Rackham O
    Cell Rep Methods; 2024 Apr; 4(4):100756. PubMed ID: 38608689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulating CRISPR/Cas9 genome-editing activity by small molecules.
    Chen S; Chen D; Liu B; Haisma HJ
    Drug Discov Today; 2022 Apr; 27(4):951-966. PubMed ID: 34823004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Advances in Improving Gene-Editing Specificity through CRISPR-Cas9 Nuclease Engineering.
    Huang X; Yang D; Zhang J; Xu J; Chen YE
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient genome editing in wheat using Cas9 and Cpf1 (AsCpf1 and LbCpf1) nucleases.
    Kim D; Hager M; Brant E; Budak H
    Funct Integr Genomics; 2021 Jul; 21(3-4):355-366. PubMed ID: 33710467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-fidelity endonuclease variant HypaCas9 facilitates accurate allele-specific gene modification in mouse zygotes.
    Ikeda A; Fujii W; Sugiura K; Naito K
    Commun Biol; 2019; 2():371. PubMed ID: 31633062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome Editing in Zebrafish Using High-Fidelity Cas9 Nucleases: Choosing the Right Nuclease for the Task.
    Prykhozhij SV; Cordeiro-Santanach A; Caceres L; Berman JN
    Methods Mol Biol; 2020; 2115():385-405. PubMed ID: 32006412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision genome editing in the CRISPR era.
    Salsman J; Dellaire G
    Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells.
    Donohoue PD; Pacesa M; Lau E; Vidal B; Irby MJ; Nyer DB; Rotstein T; Banh L; Toh MS; Gibson J; Kohrs B; Baek K; Owen ALG; Slorach EM; van Overbeek M; Fuller CK; May AP; Jinek M; Cameron P
    Mol Cell; 2021 Sep; 81(17):3637-3649.e5. PubMed ID: 34478654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplex nucleotide editing by high-fidelity Cas9 variants with improved efficiency in rice.
    Xu W; Song W; Yang Y; Wu Y; Lv X; Yuan S; Liu Y; Yang J
    BMC Plant Biol; 2019 Nov; 19(1):511. PubMed ID: 31752697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying switchable Cas9 variants to in vivo gene editing for therapeutic applications.
    Mills EM; Barlow VL; Luk LYP; Tsai YH
    Cell Biol Toxicol; 2020 Feb; 36(1):17-29. PubMed ID: 31418127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating and Enhancing Target Specificity of Gene-Editing Nucleases and Deaminases.
    Kim D; Luk K; Wolfe SA; Kim JS
    Annu Rev Biochem; 2019 Jun; 88():191-220. PubMed ID: 30883196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperactive Nickase Activity Improves Adenine Base Editing.
    Gandadireja AP; Vos PD; Siira SJ; Filipovska A; Rackham O
    ACS Synth Biol; 2024 Oct; 13(10):3128-3136. PubMed ID: 39298405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing.
    Chen X; Chen Y; Xin H; Wan T; Ping Y
    Proc Natl Acad Sci U S A; 2020 Feb; 117(5):2395-2405. PubMed ID: 31941712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
    Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
    Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
    Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted activation of diverse CRISPR-Cas systems for mammalian genome editing via proximal CRISPR targeting.
    Chen F; Ding X; Feng Y; Seebeck T; Jiang Y; Davis GD
    Nat Commun; 2017 Apr; 8():14958. PubMed ID: 28387220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR deactivation in mammalian cells using photocleavable guide RNAs.
    Zou RS; Liu Y; Ha T
    STAR Protoc; 2021 Dec; 2(4):100909. PubMed ID: 34746867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.